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Individuals undergoing chemotherapy experience drug infusions that powerfully alter 
physiological function. Chemotherapy targets cancerous cell growth, but unfortunately it also has 
widespread ramifications on normal cellular function. Among chemotherapy drugs, cardiotoxic 
chemotherapies are particularly detrimental to patients’ health. Cardiotoxic chemotherapy that 
damages heart muscle may negatively affect quality of life. PURPOSE: To assess the impact of 
cardiotoxic chemotherapy on peak oxygen uptake. We hypothesized that the calculated peak 
oxygen consumption (VO2 peak) of the female patients who have undergone cardiotoxic 
chemotherapy would be lower than that of, the female caretakers in the same age range who have 
not undergone cardiotoxic chemotherapy. METHODS: We accessed patient files from the SIUC- 
SIH Strong Survivor program and gathered data on female cancer survivors (mean age= 55.5 yo) 
and caregivers (mean age= 57.8 yo). Ten female cancer survivors were randomly selected based 
on their cardiotoxic treatment. Ten female caregivers of similar age were randomly selected, they 
had not undergone any chemotherapy. Participants’ VO2 peak was calculated using data from a 
previously administered submaximal VO2 assessment. Utilizing their recorded heart rate, age, 
treadmill walking speed and gender, an estimated VO2peak was calculated using the Ebbeling et 
al. (1991) prediction equation, VO2 peak (ml.*kg.
-1 *min-1) = 15.1 + (21.8 * Speed in mph) - 
(0.327 * HR) - (0.263 * Speed * Age) + (5 .98 * Gender) + (0.00504 * HR * Age). RESULTS: 
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An independent-samples t-test comparing the VO2 peak of cancer survivors (M= 24.373 ml*kg 
-1 
*min-1, SD ± 4.867) and their healthy counterparts (M= 25.276 ml *kg-1 *min-1, SD ±3.252) 
revealed no significant difference; t (18) = -.488, p=.632, p > .05. However, the Cohen’s D effect 
size revealed a small effect of the cardiotoxic chemotherapy (d= .218). The caregiver’s peak 
oxygen consumption is 0.218 standard deviation units above the cancer survivors VO2 peak – this 
indicates a small, yet meaningful group difference. CONCLUSION: Although the group 
difference in VO2 peak was small, these findings suggest that VO2peak may be reduced by 
cardiotoxic chemotherapy. Medical and exercise professionals should implement exercise 
programs prior to and during chemotherapy to help strengthen heart function and to limit such 
harmful effects.  
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CHAPTER 1  
INTRODUCTION 
As individuals undergo chemotherapy, they are subject to drug infusions that powerfully 
alter physiological function. Chemotherapy is designed to obstruct rapid, malignant cell division. 
Unfortunately, chemotherapy does not target cancerous cell growth alone and has widespread 
ramifications on normal cellular function. Cardiotoxic chemotherapy damages heart muscle and 
affects quality of life (Thomas, 2017). The purpose of our study was to evaluate the impact of 
cardiotoxic chemotherapy on cardiovascular output by assessing VO2 peak. Contrasting the 
cardiovascular function of chemotherapy treated patients to those who undergo different 
treatments will illuminate the effect of cardiotoxic chemotherapy. Secondarily, understanding how 
a patient’s cardiovascular output is impacted by chemotherapy, and how it differs from a patient 
who has not undergone any chemotherapy, will permit medical professionals to design patient 
specific exercise programs that attenuate the effects of cardiotoxic chemotherapy. Developing 
exercise programs that alleviate the impact of cardiotoxic chemotherapy will sustain quality of life 
and promote physical activity.  
According to the National Cancer Institute, cancer can be defined as a, “collection of 
related diseases, some of the body’s cells begin to divide without stopping and spread into 
surrounding tissues” (NCI, 2019). Cancer is a leading cause of death, worldwide; it is a genetic 
disease that fosters genetic deviations. The deviations negatively affect three gene types: proto-
oncogenes, tumor suppressor genes, and DNA repair genes. These genes are referred to as the 
“drivers” of cancer. Cancer can develop in any part of the human body. In a healthy body, cells 
grow and divide to form new cells in a highly regulated manner. Cancer cells, on the other hand, 
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are characterized by abnormal, unregulated cell division and reproduction. Unchecked 
reproduction progresses to form cancerous tumors.  
Cancer treatment depends on the type of cancer in question. Nonetheless, the most 
common cancer treatment is chemotherapy. Chemotherapy is used, “to stop or slow the growth of 
cancer cells” (NCI, 2019). Chemotherapy, radiotherapy, and surgery are among the most effective 
treatments. While chemotherapy is one of the most successful ways to treat cancer, it can cause 
serious complications. Among those is cardiotoxicity – which is known to negatively impact 
quality of life and survival rates of cancer patients. Toxic chemicals designed to fight cancer 
growth concomitantly damage the heart. The cardiac defects that arise following cardiotoxic 
chemotherapy infusion: include “left ventricular (LV) dysfunction, congestive heart failure (CHF), 
coronary vasospasm, angina, myocardial infraction, dysrhythmias, systemic hypertension, 
pericardial effusion, pulmonary fibrosis, and pulmonary hypertension” (Jain, Russell, Schwartz, 
Panjrath, & Aronow, p. 2, 2017). Cardiotoxic chemotherapy effectively treats cancerous cell 
growth. It is important to note that the impact of cardiotoxic chemotherapy is dependent on a 
host of factors. Thus, patients who undergo cardiotoxic therapy are stratified according to 
preexisting risk factors prior to treatment onset. Assessing risk factors helps doctors predict the 
corollaries of cardiotoxic treatment. According to Virizuela et al. (2018), the cardiotoxicity risk 
factors include - demographic characteristics (age & gender), previous cancer treatments, current 
anticancer treatment, hypertension, diabetes, dyslipidemia, smoking, obesity, sedentary lifestyle 
and prior or current heart diseases. The more risk factors a patient possesses, the greater the risk 
of incurring long-lasting cardiotoxic effects. As physicians document the risk factors of an 
individual, they can then decide which chemotherapy treatment will be best for them.   
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 There are several types of drugs classified as cardiotoxic. The most commonly used class 
of cardiotoxic chemotherapy drugs are; “anthracycline agents, HER2/neu blockers, alkylating 
agents, antimetabolites, antimicrotubule agents, antiangiogenic antibodies, proteasome inhibitors, 
tyrosine kinase inhibitors (TKIs), angiogenesis inhibitors, checkpoint inhibitors, histone 
deacetylase inhibitors, antiandrogens, antiestrogens, and miscellaneous” (Jain et al, 2017, p. 3). 
The list of agents under each class is extensive, for the purposes of this study, the focus was on 
the commonly used for the majority types of cancer treatment; anthracyclines, trastuzumab 
(herceptin), tyrosine kinase inhibitors, and taxanes.  
Anthracyclines agents are very effective in cancer treatment; however, cardiotoxicity is a 
major limitation with its usage. There are four common anthracyclines drugs utilized, 
“doxorubicin (DOX), daunorubicin (DNR), epirubicin (EPI), and Idarubicin (IDA)” (McGowan et 
al, 2017, p.64). The physiology behind how these agents affect the body has to do with 
anthracyclines interference with redox cycling, this interference results in a DNA damage. 
Anthracyclines are DNA and RNA synthesis inhibitors. These agents inhibit the activity of 
topoisomerase II, which is used to repair DNA. Multiple mechanisms may induce cardiotoxicity 
from these agents, some include, “oxidative injury from free radicals, peroxidation of membrane 
lipids, altered calcium handling by sarcoplasmic reticulum, and impaired protein synthesis” (Jain et 
al, 2017, p.2). Essentially these agents prevent DNA repair and DNA synthesis. Thus, after the 
cancerous cells are destroyed, there is no way the body can produce new cells due to these agents. 
Treatments with anthracyclines may induce many degenerative changes in the heart. According to 
Jain et al. (2017), these agents cause myocellular injury, left ventricle dilation, adverse remodeling 
of the heart, impaired contractility and chronic heart failure. Anthracyclines cardiotoxic effects can 
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be acute and/or chronic. Acute cardiotoxicity occurs very soon after the treatment initiation and is 
self-limiting. Acute effects such as, changes in patients ECG reading and dysrhythmias, can be 
resolved over time with assistance from family and physicians. Chronic effects are more common 
and present as left ventricular systolic dysfunction, which can lead to chronic heart failure. 
Doxorubicin, a specific anthracycline agent, is known to cause most of the chemotherapy-induced 
cardiotoxicity. In a study of young adults receiving a dosage of this agent resulted in, “abnormally 
reduced left ventricular mass and left ventricle end-diastolic posterior wall thickness… suggesting 
left ventricle remodeling” (Cao et al, 2017, p.97). Impact to this extent can truly limit a patient’s 
ability to go through day-to-day activities. Left ventricular systolic dysfunction is the most 
common risk of anthracycline cardiotoxicity. Physicians should be monitoring changes in the 
systolic function periodically during treatment. Coupling other cardiotoxic agents, such as; 
trastuzumab, tyrosine kinase inhibitors and taxanes, with anthracycline can increase the risk for 
left ventricular systolic dysfunction and chronic heart failure. 
Trastuzumab (Herceptin) agent, “is a humanized monoclonal antibody targeted against 
growth receptor protein expressed on the cell membranes” (Jain et al, 2017, p.6).  This drug is 
mainly used with breast cancer patients because of their increased HER2 activity. HER2 is a 
receptor that promotes proliferation of cell growth and trastuzumab blocks these pathways, which 
results in cell death. Trastuzumab targets the body’s immune system and acts to destroy specific 
cells. This agent causes left ventricular dysfunction and chronic heart failure, but these effects are 
reversible when treatment ceases. If the treatment does lead to chronic heart failure, then 
physicians work to modify the dosages. More than 50% of patients going through treatment with 
this agent experience left ventricular systolic dysfunction, which is an indicator for chronic heart 
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failure. In another study with this agent, researchers found that, “one-year mortality in this 
population to be 11.4% for class IV heart failure” (Moss et al, 2009, p.682). When a decrease in 
systolic function is found in patients, doctors will discontinue trastuzumab therapy. Even though 
physicians can terminate trastuzumab treatment, the decrease in systolic function will inevitably 
cause limitations in patients’ lifestyle and physical activity regimen.  
 Tyrosine kinase inhibitors (TKI), “are enzymes that activate proteins by transferring a 
phosphate group to the tyrosine residue of proteins in a single transduction cascade” (Jain et al, 
2017, p.8).  According to Jain et al (2017), these agents inhibit epidermal growth factor receptors 
and vascular endothelial growth factor signaling pathways, which lead to an inhibition of 
angiogenesis and growth. Inhibiting angiogenesis means putting an end to tumor growth, as well 
as, to the formation of new blood and lymphatic vessels. While TKI agents help stop the growth 
of cancerous tumors, they can also lead patients to develop hypertension, which eventually leads 
to left ventricular systolic dysfunction. In recent research, “eleven percent of patients receiving 
TKI agents developed CHF or a significant decrease in LVEF” (Jain et al, 2017, p.8). As shown 
in this study, this cardiotoxic agent does indeed decrease the hearts ability to pump blood; this 
severely limits what survivors can do after treatments.  
Taxanes, include paclitaxel and docetaxel are commonly used to treat lung, breast, and 
ovarian cancer. These agents, “impair normal microtubular transport systems in cardiomyocytes, 
which can impair the storage and mobilization of free fatty acids from cytosolic pool to the 
mitochondria” (Jain et al, 2017, p.9). According to Cao et al. (2016), taxanes inhibit cell division 
by repressing polymerization or depolymerization of microtubules. These agents target fast 
growing cancerous cells and enter the cell to attach to the scaffold. As they attach themselves to 
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the inside of the cancer cell, it inhibits the cell from growing.  These agents are effective when 
treating cancer, however, they do also result in chronic heart failure. Inhibiting new cell growth 
will inevitably lead to heart dysfunction.  
All four of the cardiotoxic agents discussed, impact cardiovascular function in a negative 
way. As one can conclude, evidence of a significant decrease in ejection fraction and reduced left 
ventricular systolic dysfunction is frequently seen in patients undergoing cardiotoxic treatment. 
This can limit cardiovascular function in multiple ways; limit the amount and duration of exercise, 
fatigue levels may increase, motivation to begin a program and the energy to adhere to it may 
decrease. It drastically reduces the amount of physical activity a patient can participate in.  
 The research behind how exercise impacts cardiovascular functioning in those who are 
currently undergoing chemotherapy or those who have already finished their chemotherapy 
treatment has shown very positive results.  A study in which researchers had participants perform 
moderate and high intensity exercise programs showed that, “combining high and moderate 
intensities, can reduce or minimize the cardiotoxicity of trastuzumab, increase cardiorespiratory 
fitness and health-related quality of life” (Jacquinot et al, 2017, p.9). Physicians should prescribe 
patients an exercise program and motivate them to adhere to it. Patients should participate in 
exercise even before they begin chemotherapy. Kirkham and colleagues (2018), had breast cancer 
patients participate in aerobic exercise 24 hours prior to their chemotherapy treatment. 
Participants demonstrated positive effects in physiological and musculoskeletal symptoms, as well 
as, their mood and body weight had improved. Lee et al (2018) conducted a study with high 
intensity interval training in patients undergoing anthracycline chemotherapy. In which, breast 
cancer survivors participated in an 8-week high-intensity interval training, researchers found that, 
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moderate to high intensity exercise revealed better cardiovascular outcomes. These researchers 
believe high intensity interval training is very effective with cancer patients, plus it is time efficient. 
High intensity exercise bouts provide more cardiac benefit than low-moderate exercise.  
The purpose of this study was to assess the impact of cardiotoxic chemotherapy treatment 
on peak oxygen uptake. We hypothesized that the calculated peak oxygen consumption (VO2 
peak) of the female patients who have undergone cardiotoxic chemotherapy would be lower than 
that of, the female caretakers in the same age range who have not undergone cardiotoxic 
chemotherapy. The independent variables within the study were the caregivers, who did not 
undergo chemotherapy - and the participants who had gone through cardiotoxic chemotherapy 
treatments. The dependent variable was the calculated peak oxygen consumption (VO2 peak) of 
both groups.  
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CHAPTER 2 
                                                                 METHODS 
Participants 
With permission from the SIU Human Subjects Committee and the Director of the SIUC-
SIH Strong Survivor program, participant files were accessed from the SIUC- SIH Strong 
Survivor program - from which data was gathered on cancer survivors and caregivers. Out of 
approximately 398 patient files, 283 were females, and out of those 207 were female cancer 
survivors. Out of the 207 cancer survivors, 120 had undergone cardiotoxic chemotherapy. 
Cardiotoxic chemotherapy was operationally defined as treatment with at least one of four drugs: 
anthracyclines, trastuzumab (herceptin), tyrosine kinase inhibitors, and taxanes. Based on that, ten 
female cancer survivors were randomly selected from the 120. The cancer survivors that were 
included all received their last cardiotoxic chemotherapy within the last four years. Ten female 
caregivers were age and activity level matched to the cancer survivors. All participants had 
completed an exercise history and a potential contraindication questionnaire, from which their 
daily activity levels were recorded. All participants’ heart rate, body composition, age, date of 
birth, and ethnicity was recorded. The type of cancer and type of cardiotoxic chemotherapy they 
were administered were recorded for the cancer survivors. See Figure 1.  
 
   
 
       
 
Total Participants-  
   398 
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Figure 1: Participant selection 
Procedures   
The following participant information was recorded from each file: VO2peak was 
calculated using data from a previously administered submaximal VO2 assessment. Utilizing their 
recorded heart rate, age, treadmill walking speed and gender, an estimated VO2 peak was 
calculated using the Ebbeling et al. (1991) prediction equation, VO2peak (ml*kg 
-1 *min-1) = 15.1 
+ (21.8 * Speed in mph) - (0.327 * HR) - (0.263 * Speed * Age) + (5 .98 * Gender) + (0.00504 * 
HR * Age).  
Design and Analysis 
 IBM SPSS Statistics 25 software was used to conduct an independent t-test in order to 
analyze statistical differences between the VO2 peak of the cancer survivors and caregivers. A 
significance level of alpha=0.05 was used for the independent t-test. Cohen’s D effect size was 
calculated as well using SPSS.  
 
  
 
Females - 283 Males - 115 
Cancer Survivors - 207 Caregivers - 76 
Cardiotoxic Chemotherapy - 120 
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CHAPTER 3 
                                                       RESULTS 
The participants in this study were ten cancer survivors and ten caregivers. The ten cancer 
survivors were randomly selected out of 120. The ten caregivers were age and activity level 
matched to the cancer survivors. Both cancer survivors and caregivers showed no difference in 
age, body composition, resting heart rate, level of aerobic training and level of resistance training 
(Table 1).   
Table 1: Participant Characteristics  
 Age Body 
Composition 
(BMI) 
Resting Heart 
Rate (RHR) 
Level of 
Aerobic 
training** 
Level of 
Resistance 
training** 
Cancer 
Survivors 
55.5 ± 11.03 30.4 ± 4.9 86.6 ± 10.9 2.5 ± 1.6 1.8 ± 0.79 
Caregivers  56.8 ± 7.3 28.5 ± 5.7 86.7 ± 12.4 2.8 ± 0.63 2.2 ± 0.63 
* p > 0.05 
** level of activity: 1 – very low, 2- low, 3- average, and 4- high   
 
 
The breakdown of participant files from the SIUC- SIH Strong Survivor lab.  
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Figure 2: VO2 Peak of Cancer Suvivors and Caregivers.  
Data are mean + SD 
We hypothesized that the calculated peak oxygen consumption (VO2 peak) of the female 
cancer survivors who have undergone cardiotoxic chemotherapy would be lower than that of, the 
female caretakers in the same age range who have not undergone cardiotoxic chemotherapy. To 
test this hypothesis, mean values of the VO2 peak of the cancer survivors and the caregivers were 
recorded and compared. An independent-samples t-test comparing the VO2 peak of cancer 
survivors (M= 24.4 ml*kg -1 *min-1, SD ± 4.9) and their healthy counterparts (M= 25.3 ml*kg -1 
*min-1, SD ± 3.3) revealed no significant difference; t (18) = -0.488, p=0.632, p > 0.05. However, 
the Cohen’s D effect size revealed a small effect of the cardiotoxic chemotherapy (d= 0.22). The 
caregiver’s peak oxygen consumption is 0.22 standard deviation units above the cancer survivors 
VO2 peak – this indicates a small, yet meaningful group difference. Since there was no significant 
difference seen in the participant characteristics, it would indicate that those variables did not 
influence the VO2 peak. The small effect size may have come from the cardiotoxic chemotherapy. 
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CHAPTER 4 
DISCUSSION 
The purpose of this investigation was to determine if differences in peak oxygen 
consumption (VO2 peak) exist between cancer survivors who had received cardiotoxic 
chemotherapy and caregivers who had never been administered chemotherapy. The results 
revealed that there was no significant difference in the VO2 peak between the cancer survivors and 
caregivers. Thus, our hypothesis was not be supported. However, there was a small effect size 
found from the data. The effect size indicated a lower peak oxygen uptake in the Cancer 
Survivors compared to the caregivers, indicating that cardiac function may be negatively impacted 
by cardiotoxic chemotherapy.  
In previous research, chemotherapy treatment with anthracyclines, trastuzumab 
(herceptin), tyrosine kinase inhibitors, and taxanes have found to present patients with negative 
impacts on cardiac function. These four cardiotoxic agents are mostly used in cancer treatment, 
thus leading to a multitude of complications for patients receiving this treatment. The potential of 
reversing the effects is based on how long and how often the patient is getting the treatment. 
However, in most cases, as stated in the beginning of this paper, the effects of cardiotoxic 
chemotherapy are irreversible and negatively impact on cardiac function. According to Jain et al 
(2017), evidence of a significant decrease in ejection fraction and reduced left ventricular systolic 
dysfunction is frequently seen in patients undergoing cardiotoxic treatment. The results found in 
this study indicate that there is indeed a small change in the VO2 peak between cancer survivors 
and caregivers who were age matched to the Cancer Survivors on age and activity level.  
  While the lower oxygen uptake noted in the cancer survivors in the current study has been 
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attributed to the cardiotoxic chemotherapy, there are other factors that could explain the 
differences. The exercise history and a potential contraindication questionnaire reported 
participant training levels – the activity levels for aerobic and resistance training were rated as 
being “low” or “very low” for the cancer patients. This could be explained by the decreased 
motivation and an increase in fatigue levels after treatment. The decreased levels of motivation 
and increased levels of fatigue could also be a reason why the present study did not show 
significant differences between the two groups.  
There are psychological impacts of chemotherapy, a decrease in motivation may originate 
from the time spent being inactive during treatment. The impact of cardiotoxic chemotherapy is 
not only physiological but also psychological for these participants.  
There were several limitations that would require more attention when reviewing the 
results. The biggest limitation was that the number of participants was small. Future studies 
should consider a larger population to work with, adding to the participant pool will likely result 
in significant differences. Second, undergoing chemotherapy can result in increased levels of 
fatigue perception, which may have affected the cancer survivors VO2 peak. Third, the control 
group was not screened for any prior or current health conditions.   
One way to decrease the impact of cardiotoxicity is to have patients begin an exercise 
protocol prior to chemotherapy treatment. There are many concerns for cardiovascular function 
as cancer patients start and continue going through cardiotoxic chemotherapy. However, there is 
little research to suggest anyone has had patients go through pre-chemotherapy exercise. This 
may be because of the urgency to begin treatment as soon as the diagnosis has been given. 
Medical professionals should suggest patients to begin exercise programs prior to beginning 
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chemotherapy. Rational behind this, is that, patients can potentially strengthen their systolic 
function, thus reducing the impact cardiotoxic drugs might have on it. Researchers have found 
that, “as little as 4 weeks of exercise training can significantly improve cardiac and vascular 
function” (Sturgeron, Ky, Libonati, & Schmitz, 2015, p. 5). If patients were to perform exercise 
prior to treatment, it may significantly reduce the impact of cardiotoxicity they experience. The 
focus of a future study should be on more of an intervention study, implementing an exercise 
regime with patients prior, during and after chemotherapy. While assessing their VO2 peak levels 
throughout the exercise program.   
Although the group difference in VO2 peak was small, these findings suggest that VO2 
peak may be negatively impacted by cardiotoxic chemotherapy. To avoid harmful effects from 
cardiotoxic chemotherapy, medical and exercise professionals should recommend exercise 
programs prior to beginning chemotherapy. Medical professionals can implement a moderate to 
high intensity strength endurance workout regimen (Sturgeron, Ky, Libonati, & Schmitz, 2015). 
Patients who have been diagnosed can start to formulate a plan with their physician for an 
exercise regimen. They would construct an exercise program based on their age, fitness level, 
and/or fatigue perception. The program would consist of a stationary bike, treadmill walking, if 
not weight bearing then sitting chair exercises with light weights or simple range of motion 
exercises of joints to ensure movement and increase in heart rate. As patients are going through 
this exercise program, they will start chemotherapy, the goal is for them to continue the exercise 
program through treatment and post treatment. If patients feel an increase in levels of fatigue, 
then modifications to the program can be made as they progress. Physicians should assess left 
ventricle systolic function through ECG’s and biomarkers (blood tests) to track cardiotoxicity. As 
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stated before, the goal of this exercise program is to reduce left ventricle systolic dysfunction and 
help cancer patients live a long and healthy life.  
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APPENDIX A 
Participant Characteristics   
Cancer Suvivors Age Race Cancer type Type of Cardiotoxic treatment 
1 58 Caucasian Breast Cancer Taxotere, Carboplatin – taxane 
2 48 Caucasian Breast Cancer Taxol, Adriamycin, cytoxin – taxane 
3 47 Caucasian Breast Cancer Herceptin 
4 65 Caucasian Breast Cancer Afinitor - kinase inhibitor
5 35 Caucasian Breast Cancer Trastuzumab, decetaxel, pertuzumab 
6 60 Caucasian Breast Cancer Taxotere, Herceptin 
7 45 African American Breast Cancer Doxorubicin, paclitaxel 
8 68 Caucasian Breast Cancer Taxotere, Cytoxan 
9 64 African American Uterine Cancer Paclitaxel, carboplatin 
10 65 Latin American Overian Cancer Taxotere, taxol, paclitaxel  
Caregivers Age Race 
1 65 Caucasian 
2 59 Caucasian 
3 43 Caucasian 
4 57 Caucasian 
5 65 Caucasian 
6 60 Caucasian 
7 49 Caucasian 
8 62 Caucasian 
9 58 Caucasian 
10 50 Caucasian  
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APPENDIX B 
Participant Information  
Cancer Survivors Current level of aerobic and resistance training VO2 max BMI
1 Low - Very low 21.68 ml/kg/min 27.3
2 Low - Very low 18.027 ml/kg/min 30.6
3 Low- Low 34.483 ml/kg/min 27.6
4 Low - Average 31.176 ml/kg/min 26.3
5 Low- Very low 23.094 ml/kg/min 32.7
6 Low -Low 22.136 ml/kg/min 25.5
7 Very Low- Very low 24.983 ml/kg/min 39.5
8 Low-Low 22.013 ml/kg/min 37.8
9 Average - Average 23.832 ml/kg/min 25.8
10 Very Low-  Low 22.305 ml/kg/min 31.1
Mean: 24.373 ml/kg/min 30.4
 
 
 
 
 
 
 
Caregivers  Current level of aerobic and resistance training  VO2 max  BMI 
1 Average - Low 26.916 ml/kg/min 29.2 
2 Average - Low 26.865 ml/kg/min 41.1 
3 Average - Average  22.509 ml/kg/min 26.4 
4 Low- Average  20.916 ml/kg/min 32.4 
5 Average - Low 23.176 ml/kg/min 27.4 
6 Average - Low 21.693 ml/kg/min 27.5 
7 Average - Low 26.097 ml/kg/min 26.4 
8 Low - Very low 31.776 ml/kg/min 22.3 
9 High - Average  26.957 ml/kg/min 20.8 
10 Low- Low  25.85 ml/kg/min 31.9 
Mean:  25.278 ml/kg/min 28.5 
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